Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020 Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3 long-term safety trial in migraineResults from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation, expected in 4Q 2020Phase 3 trials for AXS-05 in Alzheimer’s disease agitation and for AXS-12 in narcolepsy on track for 4Q 2020Three FDA Breakthrough Therapy designations, in MDD, Alzheimer’s disease agitation, and narcolepsy, highlight Axsome’s broad, differentiated, late-stage CNS pipeline Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2020.“Axsome is committed to developing potentially life-changing medicines for patients living with difficult-to-treat CNS disorders. Over the past several months, we achieved a number of significant clinical and regulatory milestones including receipt of Breakthrough Therapy designations from the FDA for AXS-05 for the treatment of Alzheimer’s disease agitation, and for AXS-12 for the treatment of cataplexy in patients with narcolepsy. Our industry-leading, late-stage CNS pipeline has now been granted three FDA Breakthrough Therapy designations, highlighting the potential for significant advances in patient care,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We remain on track to submit two New Drug Applications to the FDA, for AXS-05 in depression and for AXS-07 in migraine, by year-end. We expect to launch the second pivotal trial of AXS-05 in Alzheimer’s disease agitation as well as pivotal trials of AXS-12 in narcolepsy by year end. We also unveiled three new Phase 2 open-label efficacy trials of AXS-05 in three different clinically pertinent depressed populations. These trials are designed to further characterize the novel antidepressant profile of AXS-05 across a broad spectrum of patients with major depressive disorder, with results expected in the fourth quarter. Having achieved a number of key milestones and with more on the horizon, our team is expanding to support launch-readiness efforts and our growing pipeline.” CNS Pipeline UpdateAxsome is developing a portfolio of differentiated, patent-protected, central nervous system (CNS) product candidates. For the many people living with serious CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. The Company’s CNS pipeline includes four differentiated product candidates in active clinical development.AXS-05: AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is Axsome’s novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the following indications: major depressive disorder (MDD), Alzheimer’s disease (AD) agitation, and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designations for MDD, and for AD agitation; as well as Fast Track designations for treatment resistant MDD (TRD), and for AD agitation.
Depression: Axsome remains on track to submit a New Drug Application (NDA) to the FDA for AXS-05 for the treatment of MDD in the fourth quarter of 2020. In July 2020, Axsome announced it had completed a pre-NDA meeting for AXS-05 in MDD with the FDA to reach agreement on the proposed content and format of the Company’s planned NDA submission, including the clinical and nonclinical requirements. Based on the feedback from the FDA, the Company believes its regulatory data package will be sufficient to support an NDA for AXS-05 in MDD. The NDA is supported by positive efficacy results from the ASCEND and GEMINI trials.
Enrollment has been completed in the COMET (Clinical Outcomes with NMDA-based Depression Treatment) Phase 3 open-label, long-term safety trial to support the planned NDA filing of AXS-05 in MDD. Nearly 900 patients have been enrolled, more than 500 of whom have been treated with AXS-05 for at least 6 months to date. At least 300 patients treated for 6 months and 100 patients treated for one year are required for the NDA filing. Axsome remains on track to achieve the required number of patients treated for one year in the fourth quarter.
Axsome is conducting three Phase 2 open-label efficacy sub-studies of the COMET trial which will evaluate the efficacy and safety of AXS-05 in three clinically pertinent MDD patient populations: the COMET-TRD trial in treatment resistant MDD (TRD), the COMET-AU trial in antidepressant unresponsive MDD, and the COMET-SI trial in MDD with suicidal ideation. Efficacy results from these studies are expected in the fourth quarter of 2020.
Axsome has initiated the MERIT (Mechanistic Evaluation of Response in TRD) trial, a Phase 2, double-blind, placebo-controlled, randomized withdrawal study in patients with TRD. Results from the MERIT trial are expected in the first half of 2021. The MERIT and COMET-TRD trials are being conducted in lieu of the previously planned Phase 3 trial in TRD. This approach will more quickly generate clinically useful information with AXS-05 in this treatment resistant MDD population, starting as early as the fourth quarter of 2020.
AD Agitation: In June 2020, Axsome received FDA Breakthrough Therapy designation for AXS-05 for the treatment of AD agitation. The designation was supported by the positive results from the pivotal ADVANCE-1 study, a randomized, double-blind, controlled, multicenter U.S. trial in which 366 Alzheimer’s disease patients were treated with AXS-05, bupropion, or placebo. Axsome remains on track to initiate a second Phase 3 trial of AXS-05 in AD agitation in the second half of 2020.
Smoking Cessation: Axsome plans to meet with the FDA in the second half of 2020 to discuss the continued clinical development of AXS-05 as an aid to smoking cessation treatment. Axsome previously announced positive results from a Phase 2 trial of AXS-05 for smoking cessation treatment conducted under a research collaboration between Axsome and Duke University.
AXS-07: AXS-07 (MoSEIC™ meloxicam/rizatriptan) is Axsome’s novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine.
Migraine: Axsome remains on track to submit an NDA for AXS-07 in the acute treatment of migraine to the FDA in the fourth quarter of 2020. The NDA is supported by positive efficacy results from the MOMENTUM and INTERCEPT trials.
Enrollment has been completed in the MOVEMENT (Multimechanistic Treatment Overtime of Migraine Symptoms) Phase 3 open-label, long-term safety trial to support the planned NDA filing of AXS-07 in the acute treatment of migraine. More than 700 patients have been enrolled, approximately 450 of whom have been treated with AXS-07 for at least 6 months to date. At least 300 patients treated for 6 months and 100 patients treated for one year are required for the NDA filing. Axsome remains on track to achieve the required number of patients treated for one year in the third quarter.
AXS-12: AXS-12 (reboxetine) is Axsome’s novel, oral, potent, and highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. AXS-12 has been granted FDA Breakthrough Therapy designation for the treatment of cataplexy in patients with narcolepsy and Orphan Drug Designation for the treatment of narcolepsy.
Narcolepsy: In August 2020, Axsome received FDA Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy. The designation was supported by the positive results from the Phase 2 CONCERT study, a randomized, double-blind, placebo-controlled, crossover, multicenter U.S. trial in which 21 patients with a diagnosis of narcolepsy with cataplexy were treated with AXS-12 or with placebo, followed by a crossover to the other treatment. Axsome is on track to initiate Phase 3 trials of AXS-12 in the treatment of narcolepsy in the second half of 2020.
AXS-14: AXS-14 (esreboxetine) is Axsome’s novel, oral, potent, and highly selective norepinephrine reuptake inhibitor for the treatment of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.
Fibromyalgia: Axsome plans to meet with the FDA in the second half of 2020 to discuss the further clinical development of AXS-14 for the treatment of fibromyalgia. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and a Phase 2 trial in the treatment of fibromyalgia.
Anticipated MilestonesNDA Submissions:AXS-05 in the treatment of MDD (4Q 2020)AXS-07 in the acute treatment of migraine (4Q 2020)FDA Meetings:AXS-05 for AD agitation (2H 2020)AXS-05 for smoking cessation (2H 2020)AXS-12 for narcolepsy (2H 2020)AXS-14 for fibromyalgia (2H 2020)Clinical Trial Readouts:Phase 2 COMET-TRD trial of AXS-05 in TRD, topline data (4Q 2020)Phase 2 COMET-AU trial of AXS-05 in antidepressant unresponsive MDD, topline data (4Q 2020)Phase 2 COMET-SI trial of AXS-05 in MDD with suicidal ideation, topline data (4Q 2020)Phase 2 MERIT trial of AXS-05 in TRD, topline data (1H 2021)Clinical Trial Initiations:Phase 3 trials of AXS-12 in narcolepsy (2H 2020)Phase 3 trial of AXS-05 in AD agitation (2H 2020)Second Quarter 2020 Financial ResultsResearch and development (R&D) expenses: R&D expenses were $10.5 million for the quarter ended June 30, 2020 and $11.0 million for the comparable period in 2019. The decrease of $0.5 million was driven by the completion of several clinical trials which were ongoing in the comparable period in 2019.General and administrative (G&A) expenses: G&A expenses were $7.2 million for the quarter ended June 30, 2020 and $2.4 million for the comparable period in 2019. The change was primarily due to an increase in stock compensation expense, along with the build-out of the commercial function.Net loss: Net loss was $18.3 million, or $(0.49) per share for the quarter ended June 30, 2020, compared to a net loss of $13.8 million, or $(0.41) per share for the comparable period in 2019.Cash: At June 30, 2020, Axsome had $190.7 million of cash compared to $197.3 million of cash at March 31, 2020.Shares outstanding: At June 30, 2020, Axsome had 37,267,510 shares of common stock outstanding.Financial guidance: Axsome believes that its cash at June 30, 2020 will be sufficient to fund the company’s anticipated operations, based on its current operating plans, for at least two years.Conference Call InformationAxsome will host a conference call and webcast today at 8:00 AM Eastern to discuss second quarter 2020 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (844) 698-4029 (toll-free domestic) or (647) 253-8660 (international), and use the conference ID 4876676. The live webcast can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.About Axsome Therapeutics, Inc.Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome’s core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), treatment resistant depression (TRD), Alzheimer’s disease (AD) agitation, and as treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.Forward Looking StatementsCertain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, FDA’s agreement with the Company’s discontinuation of the bupropion treatment arm of the ADVANCE-1 study in accordance with the independent data monitoring committee’s recommendations); the potential for the MOMENTUM clinical trial to provide a basis for approval of AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment; the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.Axsome Therapeutics, Inc.
Selected Consolidated Financial DataStatements of Operations Information:Balance Sheet Information:
Axsome Contact:
Mark Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
22 Cortlandt Street, 16th Floor
New York, NY 10007
Tel: 212-332-3243
Email: [email protected]
www.axsome.com
Bay Street News
